Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT01930162 | Safety and Tolerability of HSC835 in Patients With Hematological Malignancies Undergoing Single Umbilical Cord Blood Transplant | PHASE2 | COMPLETED | 9 | — | — | Oct 7, 2014 | Aug 29, 2016 | Jan 5, 2021 | 1 | United States |
This endpoint was to study safety and tolerability of HSC835 as measured by the absence of graft failure at day 42 in excess of that currently observed with double umbilical cord blood (UCB) transplantation (DUCBT) with non-myeloablative (NMA) conditioning.
| Arm | Type | Description |
|---|---|---|
| HSC835 | EXPERIMENTAL | Patients with hematologic malignancies requiring UCB transplant with a NMA conditioning regimen. |
| Name | Type | Description |
|---|---|---|
| HSC835 | DRUG | HSC835 is a stem cell therapy product providing a source of Hematopoietic stem cell (HSC). |
Inclusion Criteria: * Patients with a diagnosis that qualifies them for UCBT * Adequate organ function * Availability of eligible donor material Exclusion Criteria: * Pregnancy or breastfeeding women and women of child-bearing potential unless two acceptable forms of contraception are being used ...